PAMIDRONIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3H11NO7P2
Molecular Weight	235.0695
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=WRUUGTRCQOWXEG-UHFFFAOYSA-N

InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)

HIDE SMILES / InChI

Molecular Formula	C3H11NO7P2
Molecular Weight	235.0695
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

Pamidronic acid (Pamidronate Disodium) is a bone resorption inhibitor. The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment of hypercalcemia, pamidronate disodium inhibits bone resorption apparently without inhibiting bone formation and mineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that pamidronate disodium inhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by various tumors in animal studies. Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18327899 \| https://www.ncbi.nlm.nih.gov/pubmed/10620343 \| https://www.ncbi.nlm.nih.gov/pubmed/11160603	Inhibitor 8504		55.9 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Malignant hypercalcemia 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8583	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991
Paget's disease 16 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8583	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991
Osteolytic bone metastases of breast cancer 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8583	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991

C_max

Value	Dose	Analyte	Population
1.92 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9115053/	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.73 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.44 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.61 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9115053/	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.6 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 5.6 mg/kg, 3 times / day Route: oral Route: multiple Dose: 5.6 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf
120 mg/kg 1 times / day multiple, intravenous Overdose Dose: 120 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Fever, Hypotension... AEs leading to discontinuation/dose reduction: Fever Hypotension Taste perversion Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Interstitial pneumonitis, Hypocalcemia... AEs leading to discontinuation/dose reduction: Interstitial pneumonitis Hypocalcemia Bone pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf

AEs

AE	Significance	Dose	Population
Diarrhea	Disc. AE	5.6 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 5.6 mg/kg, 3 times / day Route: oral Route: multiple Dose: 5.6 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf
Hypocalcemia	Disc. AE	120 mg/kg 1 times / day multiple, intravenous Overdose Dose: 120 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Fever	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Hypotension	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Taste perversion	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Bone pain	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Hypocalcemia	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Interstitial pneumonitis	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCTN2 71 OCTN1 32	CYP 303 UGT 219

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OCTN1 32	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/B978178242076750006X	yes
OCTN2 71	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/B978178242076750006X	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf#page=1 Page: 1.0	no
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf#page=1 Page: 1.0	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY553353	https://www.001chemical.com/chem/40391-99-9
3B Scientific (Wuhan) Corp	3B2-1670	http://www.3bsc.com/index/pro_info.php?id=55389
AA Blocks	AA00732G	https://www.aablocks.com/goods/Goods/detail?id=AA00732G
Aaron Chemicals	AR0073U8	http://www.aaronchem.com/40391-99-9
abcr GmbH	AB492176	http://www.abcr.com/shop/en/AB492176
Acadechem	ACDS-033198	http://www.acadechemical.com/product/107897
Achemtek	0104-020132	http://www.achemtek.com/40391-99-9
Adooq BioScience	A11685	https://www.adooq.com/pamidronic-acid.html
AEchem Scientific Corp., USA	AE032040	http://www.aechemsc.com/info_products/AE032040.php
AK Scientific, Inc. (AKSCI)	2631AH	http://www.aksci.com/item_detail.php?cat=2631AH
Angel Pharmatech	AG111246	http://www.angelpharmatech.com/40391-99-9.html
ApexBio Technology	B1807	http://www.apexbt.com/pamidronate.html
Ark Pharm	AK113121	http://www.arkpharminc.com/products/40391-99-9.html
Aurora Fine Chemicals LLC	A13.111.373	http://online.aurorafinechemicals.com/info?ID=A13.111.373
AvaChem Scientific	2606A	http://www.avachem.com/productSearch.asp?2606A
BioChemPartner	BCP17709	http://www.biochempartner.com/40391-99-9-BCP17709
BioCrick	BCC4693	http://www.biocrick.com/Pamidronate-BCC4693.html
BLD Pharm	BD01332989	http://www.bldpharm.com/products/1159812-33-5.html
BLD Pharm	BD146697	http://www.bldpharm.com/products/40391-99-9.html
Chem Scene	CS-7787	http://www.chemscene.com/40391-99-9.html
ChemMol	99097528	http://www.chemmol.com/chemmol/99097528.html
Chemspace	CSSB00000052565	https://chem-space.com/CSSB00000052565
Clearsynth	CS-O-02157	https://www.clearsynth.com/en/CSO02157.html
Clearsynth	CS-O-30893	http://www.clearsynth.com/en/CSO30893.html
CSNpharm	CSN11650	https://www.csnpharm.com/products/pamidronic-acid.html
DC Chemicals	DCAPI1175	http://www.dcchemicals.com//product_show-Pamidronic_acid.html
Debye Scientific	DB-049579	http://www.debyesci.com/cas_40391-99-9.html
eNovation Chemicals	D280137	https://www.enovationchem.com/ProductDetails.asp?ProductID=D280137
eNovation Chemicals	Y1047107	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1047107
Finetech	FT-0630610	http://www.finetechnology-ind.com/prod/detail/pub/40391-99-9.html
Hairui	HR124492	http://www.hairuichem.com/en/product/40391-99-9.html
iChemical	EBD36833	http://www.ichemical.com/products/40391-99-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-4373491291	https://mcule.com/MCULE-4373491291/
MedChem Express	HY-B0012	https://www.medchemexpress.com/Pamidronic_acid.html
Molcore	MC553353	https://www.molcore.com/product/40391-99-9
MuseChem	R003777	https://www.musechem.com/product/R003777.html
OChem	7839	http://www.ocheminc.com/index.php?act=psearch&pid=391P999
Selleck Chemicals	S2063	http://www.selleckchem.com/products/pamidronic-acid.html
Sinfoo Biotech	S017541	http://www.sinfoobiotech.com/product/1020939
Smolecule	S591193	https://www.smolecule.com/products/s591193
THE BioTek	bt-308550	https://www.thebiotek.com/product/others/bt-308550
Vesino Industrial Co Ltd	VA11481	http://www.vsnchem.com/goto/product/22804/

PubMed

Title	Date	PubMed
Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.	2001-12	11721169
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.	2001-11-06	11693896
Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.	2001-11-01	11673519
[Two cases of effective weekly paclitaxel administration for metastatic breast cancer].	2001-11	11729485
Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.	2001-11	11719835
Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.	2001-11	11697801
Antibacterial effect of human V gamma 2V delta 2 T cells in vivo.	2001-11	11696580
Prevention of bone loss and fracture after lung transplantation: a pilot study.	2001-10-15	11602851
Paget's disease of the spine and its management.	2001-10	11718191
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.	2001-10	11680835
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.	2001-10	11595616
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.	2001-10	11593054
The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease.	2001-10	11567178
Trastuzumab and breast cancer.	2001-09-27	11575298
Bone loss accompanying medical therapies.	2001-09-27	11575293
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.	2001-09-27	11575286
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.	2001-09-07	11435429
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.	2001-09-01	11520816
Hypercalcemia in patients with oral squamous cell carcinoma.	2001-09	11642565
Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits.	2001-09	11603525
Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.	2001-09	11589787
Bisphosphonates for osteoporosis.	2001-09	11586803
Isoprenoid biosynthesis. Metabolite profiling of peppermint oil gland secretory cells and application to herbicide target analysis.	2001-09	11553758
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.	2001-09	11547843
Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: suggested therapeutic approach.	2001-09	11533372
Adjuvant bisphosphonate therapy: the future.	2001-08	11544582
Dosing regimens and main adverse events of bisphosphonates.	2001-08	11544576
Analysis of skeletal-related events in breast cancer and response to therapy.	2001-08	11544572
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats.	2001-08	11519698
Idiopathic orbital inflammation following intravenous pamidronate.	2001-08	11511778
Pamidronate in incident pain due to bone metastases.	2001-08	11503631
Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).	2001-08	11452173
Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.	2001-07-19	11463032
Bisphosphonates may be useful in treatment of bone metastases.	2001-07-18	11459865
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.	2001-07-15	11454892
Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.	2001-07	11518261
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].	2001-07	11508158
Ocular adverse effects of alendronic acid.	2001-06	11718170
[Chronic recurrent multifocal osteomyelitis in children: report of 17 cases].	2001-06	11446177
[Analgesic effect of Pamidronate on bone pain in patient with hypertrophic pulmonary osteoarthropathy].	2001-06	11416808
Disease controlling antirheumatic therapy in spondyloarthropathy.	2001-06	11409153
Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.	2001-05	11683535
Bisphosphonates in multiple myeloma.	2001	11687178
Bisphosphonates for osteoporosis in people with cystic fibrosis.	2001	11687132
Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.	2001	11596836
[Paget disease or fibrous dysplasia of the radius?--A case report].	2001	11582993
The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.	2001	11511021
Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia.	2001	11477309
[Vertebral osteoporosis induced by corticoids and cyclosporine ina a patient with Still disease].	2001	11474883
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.	2001	11438040

Patents

Sample Use Guides

In Vivo Use Guide

Moderate Hypercalcemia The recommended dose of pamidronate disodium in moderate hypercalcemia (corrected serum calcium* of approximately 12 to 13.5 mg/dL) is 60 to 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency. Severe Hypercalcemia The recommended dose of pamidronate disodium in severe hypercalcemia (corrected serum calcium* >13.5 mg/dL) is 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency.

Route of Administration: Intravenous

In Vitro Use Guide

BMSCs proliferation was significantly inhibited with 10(−4) M Pamidronic acid (pamidronate) after 72h and 168h, and with 6 × 10(−5) M pamidronate after 168h. Alveolar osteoblasts cultured in osteogenic medium exhibited significantly lower alkaline phosphatase (AP) activities with 6 × 10(−5) M and 10(−4) M pamidronate (39% and 16% of the unsupplemented group) as compared to all lower concentration groups after 168h.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:25:33 GMT 2025` Edited by `admin` on `Mon Mar 31 21:25:33 GMT 2025`
Record UNII	OYY3447OMC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PAMIDRONIC ACID

Official Name

English

PAMIDRONATE

Preferred Name

English

(3-AMINO-1-HYDROXYPROPYLIDENE)BISPHOSPHONIC ACID

Systematic Name

English

DIHYDROGEN (3-AMINO-1-HYDROXYPROPYLIDENE)DIPHOSPHONATE

Systematic Name

English

(3-AMINO-1-HYDROXYPROPYLIDENE)DIPHOSPHONIC ACID

Systematic Name

English

PAMIDRONIC ACID [MI]

Common Name

English

pamidronic acid [INN]

Common Name

English

3-AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONIC ACID

Systematic Name

English

Pamidronic acid [WHO-DD]

Common Name

English

PHOSPHONIC ACID, (3-AMINO-1-HYDROXYPROPYLIDENE)BIS-

Common Name

English

PAMIDRONATE [VANDF]

Common Name

English

RIBODROAT

Brand Name

English

PAMIDRONATE [MART.]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000007707

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

NCI_THESAURUS

C67439

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

NCI_THESAURUS

C443

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

WHO-VATC

QM05BA03

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

LIVERTOX

735

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

NDF-RT

N0000175579

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

WHO-ATC

M05BA03

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

Code System Code Type Description

MESH

C019248

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

ChEMBL

CHEMBL834

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

INN

6305

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

WIKIPEDIA

Pamidronic acid

Created by admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025

PRIMARY

ECHA (EC/EINECS)

254-905-2

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

NCI_THESAURUS

C61875

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

EVMPD

SUB09598MIG

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

CAS

40391-99-9

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

LACTMED

Pamidronate

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

DAILYMED

OYY3447OMC

Created by admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025

PRIMARY

PUBCHEM

4674

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

EPA CompTox

DTXSID4023414

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

RXCUI

1546406

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

RXCUI

11473

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

ALTERNATIVE

FDA UNII

OYY3447OMC

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

IUPHAR

7259

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

MERCK INDEX

m8374

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

Merck Index

SMS_ID

100000092288

Created by admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025

PRIMARY

DRUG CENTRAL

2048

Created by admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025

PRIMARY

DRUG BANK

DB00282

Created by admin on Mon Mar 31 21:25:33 GMT 2025 , Edited by admin on Mon Mar 31 21:25:33 GMT 2025

PRIMARY

Related Record Type Details


					C7S8VWP5DH

PAMIDRONATE DISODIUM ANHYDROUS

SALT/SOLVATE -> PARENT


					MUA93Q6K1J

PAMIDRONATE MONOSODIUM

SALT/SOLVATE -> PARENT


					8742T8ZQZA

PAMIDRONATE DISODIUM

SALT/SOLVATE -> PARENT

Related Record Type Details


					OYY3447OMC

PAMIDRONIC ACID

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

C_max

T_1/2

Drug as perpetrator